$4.19+0.12 (+2.95%)
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system.
X4 Pharmaceuticals, Inc. in the Healthcare sector is trading at $4.19. The stock is currently near its 52-week high of $4.83, remaining 19.7% above its 200-day moving average. Technical signals show neutral RSI of 52 and bearish MACD signal, explaining why XFOR maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective a...
Insiders were net buyers of X4 Pharmaceuticals, Inc.'s ( NASDAQ:XFOR ) stock during the past year. That is, insiders...
X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +38.89% and +53.22%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
BOSTON (AP) — X4 Pharmaceuticals, Inc. XFOR) on Tuesday reported a loss of $23.9 million in its fourth quarter. On a per-share basis, the Boston-based company said it had a loss of 22 cents.
ProQR (PRQR) delivered earnings and revenue surprises of -12.50% and -36.14%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Analyst sentiment across three small-cap biotechs has turned notably positive, with fresh coverage initiations and maintained Buy-equivalent ratings from institutional research desks ahead of 2026 clinical catalysts. All three names carry verified Buy or Overweight ratings, and the gap between current trading prices and analyst targets ranges from substantial to dramatic. Three Calls, Three Catalysts ... X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention